Expertise in
42
conditions

Dr. Elizabeth H. Cull

Prisma Health University Medical Group
Greenville, SC
Expertise in
42
conditions
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Expertise in
42
conditions
OverviewInsuranceLocationsClinical Research

Overview

Elizabeth Cull is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Cull is highly rated in 42 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Cull is currently accepting new patients.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Prisma Health Greer Memorial Hospital
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Prisma Health Hillcrest Hospital
Languages Spoken
English
Gender
Female

Insurance

MediFind strives to display the most accurate insurance information for every doctor. Please contact your provider to confirm if they accept your insurance.

Dr. Elizabeth H. Cull accepts the following insurance:

  •  Cigna
  •  Blue Cross Blue Shield
  •  Humana

Locations

PRISMA HEALTH UNIVERSITY MEDICAL GROUP
65 International Dr, Greenville, SC 29615
864-987-7000
Other Locations
PRISMA HEALTH UNIVERSITY MEDICAL GROUP
210 Freeman Farm Rd, Duncan, SC 29334
864-968-5123
PRISMA HEALTH UNIVERSITY MEDICAL GROUP
175 Patewood Dr, Greenville, SC 29615
864-797-1403
PRISMA HEALTH UNIVERSITY MEDICAL GROUP
701 Grove Rd, Greenville, SC 29605

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: May 20, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Suspended
Publish Date: January 25, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: May 20, 2021
Intervention Type: Biological
Study Drugs: Rituximab, Obinutuzumab, Idelalisib, Ibrutinib, Bendamustine, TRU-016
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 9 Less Clinical Trials

16 Total Publications

Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Journal: Journal of adolescent and young adult oncology
Published: July 03, 2024
Similar Doctors
Expertise in
45
conditions
Dr. Suzanne R. Fanning
Hematology Oncology | Hematology | Oncology
Expertise in
45
conditions
Dr. Suzanne R. Fanning
Hematology Oncology | Hematology | Oncology

Prisma Health University Medical Group

65 International Dr, 
Greenville, SC 
Accepting New Patients
Offers Telehealth
Languages Spoken English

Suzanne Fanning is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Fanning is highly rated in 45 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Fanning is currently accepting new patients.

Expertise in
83
conditions
Dr. Britt H. Bolemon
Hematology Oncology | Hematology | Oncology
Expertise in
83
conditions
Dr. Britt H. Bolemon
Hematology Oncology | Hematology | Oncology

Prisma Health University Medical Group

890 W Faris Rd, 
Greenville, SC 
 5.9 mi
Accepting New Patients
Offers Telehealth
Languages Spoken English

Britt Bolemon is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Bolemon is highly rated in 83 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Bolemon is currently accepting new patients.

Expertise in
22
conditions
Dr. Carla W. Jorgensen
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. Carla W. Jorgensen
Hematology Oncology | Hematology | Oncology

Prisma Health University Medical Group

3 Butternut Dr, Suite B, 
Greenville, SC 
 6.2 mi
Accepting New Patients
Languages Spoken English

Carla Jorgensen is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Jorgensen is highly rated in 22 conditions, according to our data. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Thyroidectomy. Dr. Jorgensen is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile